

Anthony J Olszanski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/132367/publications.pdf>

Version: 2024-02-01

84
papers

5,332
citations

186265

28
h-index

91884

69
g-index

87
all docs

87
docs citations

87
times ranked

8444
citing authors

#	ARTICLE	IF	CITATIONS
1	Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. <i>Cell</i> , 2017, 170, 1109-1119.e10.	28.9	1,124
2	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.	4.9	393
3	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	4.9	326
4	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 230-241.	4.9	284
5	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018, 36, 3223-3230.	1.6	267
6	Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 450-473.	4.9	203
7	Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 3836-3841.	1.6	176
8	Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 3841-3849.	7.0	173
9	NCCN Guidelines Insights: Melanoma: Cutaneous, Version 2.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 364-376.	4.9	167
10	Phase I Dose-Escalation Study of LCL161, an Oral Inhibitor of Apoptosis Proteins Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 3103-3110.	1.6	160
11	First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 5703-5710.	7.0	160
12	Melanoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 395-407.	4.9	134
13	Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 2059-2066.	1.6	127
14	Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 387-405.	4.9	124
15	A Phase I/II Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. <i>Cancer Discovery</i> , 2019, 9, 384-395.	9.4	88
16	Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2009, 27, 5262-5269.	1.6	80
17	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	4.9	76
18	Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850). <i>Clinical Cancer Research</i> , 2006, 12, 7079-7085.	7.0	68

#	ARTICLE	IF	CITATIONS
19	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65
20	Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 366-400.	4.9	63
21	Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. , 2020, 8, e001006.		62
22	Melanoma, Version 4.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 621-629.	4.9	61
23	Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma. Journal of Managed Care Pharmacy, 2014, 20, 346-356.	2.2	57
24	Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. Journal of Clinical Investigation, 2018, 128, 2325-2338.	8.2	52
25	Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Investigational New Drugs, 2015, 33, 1040-1047.	2.6	50
26	OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 460-472.	7.0	48
27	Clinical Activity and Safety of Combination Therapy with Temezirolimus and Bevacizumab for Advanced Melanoma: A Phase II Trial (CTEP 7190/Mel47). Clinical Cancer Research, 2013, 19, 3611-3620.	7.0	46
28	Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Annals of Oncology, 2014, 25, 132-138.	1.2	36
29	An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2019, 25, 6709-6720.	7.0	32
30	Outcomes in patients with mucosal melanomas. Journal of Surgical Oncology, 2013, 108, 516-520.	1.7	29
31	Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. , 2016, 4, 8.		28
32	Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. British Journal of Cancer, 2012, 107, 1277-1285.	6.4	26
33	Two Phase 1 dose-escalation studies exploring multiple regimens of ltronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 2017, 79, 315-326.	2.3	25
34	Pharmacokinetic evaluation of axitinib. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 259-270.	3.3	24
35	Donor-Derived Metastatic Melanoma and Checkpoint Inhibition. Transplantation Proceedings, 2017, 49, 1551-1554.	0.6	24
36	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1337-1346.	4.9	23

#	ARTICLE	IF	CITATIONS
37	Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2012, 107, 1268-1276.	6.4	20
38	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer. , 2022, 10, e003581.		19
39	NCCN Working Group Report: Designing Clinical Trials in the Era of Multiple Biomarkers and Targeted Therapies. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1629-1649.	4.9	18
40	Oxaliplatin: Detection and Management of Hypersensitivity Reactions. , 2019, 23, 68-75.		18
41	Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. <i>Oncotarget</i> , 2020, 11, 3118-3128.	1.8	18
42	Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors. <i>Investigational New Drugs</i> , 2022, 40, 596-605.	2.6	18
43	Progress in the Management of Melanoma in 2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 645-648.	4.9	17
44	Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 479-488.	7.0	16
45	Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. <i>British Journal of Cancer</i> , 2010, 103, 1554-1561.	6.4	15
46	Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 160-166.	4.9	15
47	Phase I and Pharmacokinetic Study of AI-850, A Novel Microparticle Hydrophobic Drug Delivery System for Paclitaxel. <i>Clinical Cancer Research</i> , 2007, 13, 3293-3301.	7.0	14
48	Successful Imatinib Therapy for Neuroendocrine Carcinoma With ActivatingKITMutation: A Case Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 847-852.	4.9	14
49	Feasibility and safety of targeting mitochondria for cancer therapy “ preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor. <i>Cancer Biology and Therapy</i> , 2022, 23, 117-126.	3.4	13
50	NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 120-131.	4.9	11
51	Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1206-1216.	2.6	10
52	Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 87-95.	2.3	9
53	Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. <i>Pharmaceutical Medicine</i> , 2020, 34, 83-91.	1.9	9
54	Principles of Immunotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 670-672.	4.9	8

#	ARTICLE	IF	CITATIONS
55	A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2021, 39, 1613-1623.	2.6	8
56	Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 393-398.	1.3	7
57	The Effect of Food on the Absorption of Abiraterone Acetate from a Fine Particle Dosage Form: A Randomized Crossover Trial in Healthy Volunteers. <i>Oncology and Therapy</i> , 2017, 5, 161-170.	2.6	7
58	Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 479-486.	2.3	6
59	First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. <i>Annals of Oncology</i> , 2018, 29, viii404.	1.2	6
60	First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 147-158.	2.6	5
61	Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 878-888.	3.3	5
62	Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, S-1-S-5.	4.9	5
63	The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1291-1302.	2.4	3
64	A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2670-TPS2670.	1.6	3
65	Impact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma. <i>Journal of Surgical Research</i> , 2020, 254, 147-153.	1.6	3
66	Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, 79-87.	1.2	3
67	Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. <i>Anti-Cancer Drugs</i> , 2015, 26, 785-792.	1.4	2
68	Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2016, 21, 402.	3.7	2
69	Metastatic Melanoma With Leptomeningeal Disease. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 79-83.	0.4	2
70	DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS9594-TPS9594.	1.6	2
71	Absorption of a novel formulation of abiraterone acetate (AA) fine particle (AAFP) under fed and fasted conditions.. <i>Journal of Clinical Oncology</i> , 2017, 35, e606-e606.	1.6	1
72	Immune Checkpoint Inhibitor-Based Therapy as a Backbone in Cancer Treatment. <i>Journal of the Advanced Practitioner in Oncology</i> , 2020, 11, 231-233.	0.4	1

#	ARTICLE	IF	CITATIONS
73	Evolving Paradigms in Melanoma Therapy. Journal of the Advanced Practitioner in Oncology, 2016, 7, 291-294.	0.4	1
74	Orally Administered Cancer Therapy: Breaking Down Barriers to Adherence and Quality of Life. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 290-292.	4.9	1
75	Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. Cancer Chemotherapy and Pharmacology, 2016, 78, 929-939.	2.3	0
76	P2.03a-018 A Phase I/II Study of Alisertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC. Journal of Thoracic Oncology, 2017, 12, S898-S899.	1.1	0
77	Melanoma in the Bronchus. New England Journal of Medicine, 2018, 379, e36.	27.0	0
78	Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.. Journal of Clinical Oncology, 2021, 39, TPS2667-TPS2667.	1.6	0
79	An Open-Label, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Pralatrexate in Relapsed/Refractory Advanced Solid Tumors or Advanced Lymphoma/Myeloma Patients with Mild, Moderate, and Severe Renal Impairment. Blood, 2015, 126, 3966-3966.	1.4	0
80	Biomarkers and stage II colorectal cancer therapy. Translational Cancer Research, 2016, 5, S84-S86.	1.0	0
81	Advances in the Use of Immunotherapy in Oncology. Journal of the Advanced Practitioner in Oncology, 2017, 8, 221-225.	0.4	0
82	Creating Clarity in Metastatic Melanoma: Optimizing Treatment and Improving Outcomes. Journal of the Advanced Practitioner in Oncology, 2020, 11, 280-283.	0.4	0
83	Does the order of factors affect the product? Lessons learned from the TORCH trial. Translational Lung Cancer Research, 2013, 2, 50-4.	2.8	0
84	Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 615-617.	4.9	0